Abstract: Disclosed are geminoid peptide-like compound according to Formula I: R1—C(?O)—Zn—NR3-R2??(I) in which R1 and R2 are each independently saturated, partly saturated or unsaturated, straight, branched or cyclic alkyl chains, wherein R1 has a number of C atoms of 11 or more, preferably 11 to 19, and R2 has a number of C atoms of 12 or more, preferably 12 to 20; R3 is hydrogen or C1-C6 alkyl; n is an integer from 1-15; each Z independently is an amino acid residue, wherein Zn comprises an N-terminus attached to C(?O) and a C-terminus that is attached to NR3, for use as a medicament.

Abstract: Disclosed are geminoid peptide-like compound according to Formula (I): R1—C(=0)-Zn—NR3—R2 in which R1 and R2 are each independently saturated, partly saturated or unsaturated, straight, branched or cyclic alkyl chains, wherein R1 has a number of C atoms of 11 or more, preferably 11 to 19, and R2 has a number of C atoms of 12 or more, preferably 12 to 20; R3 is hydrogen or C1-C-6 alkyl; n is an integer from 1-15; each Z independently is an amino acid residue, wherein Zn comprises an N-terminus attached to C(=0) and a C-terminus that is attached to NR3, for use as a medicament.

Abstract: The present invention relates to a gene delivery vehicle comprising a general nucleic acid binding domain and an integrin binding domain. Typically, the at least two different domains of the gene delivery vehicle are somehow linked. The gene delivery vehicle may be used to deliver a therapeutic molecule to a cell exposing integrin to, at least in part, enhance the efficacy of gene delivery using integrin receptors. In one embodiment, the integrin binding domain is derived from the C-terminal region of the Yersinia pseudotuberculosis invasin or a functional homologue thereof.